| Literature DB >> 33761714 |
Lingyun Zhao1, Xi Wang2, Ying Xiong1, Yanqing Fan3, Yiwu Zhou4, Wenzhen Zhu1.
Abstract
ABSTRACT: We aimed to investigate the relationship of radiological features and the corresponding pulmonary pathology of patients with Coronavirus Disease (COVID-19) pneumonia.In this multicenter study, serial chest CT and radiographic images from 9 patients (51-85 years old, 56% male) were reviewed and analyzed. Postmortem lungs were sampled and studied from these autopsies, with a special focus on several corresponding sites based on imaging features.The predominant pattern of pulmonary injury in these 9 cases was diffuse alveolar damage (DAD) and interstitial inflammation. Moreover, acute fibrinous exudates, organization, inflammatory cell infiltration, hyaline membranes, pulmonary edema, pneumocyte hyperplasia, and fibrosis were all observed. The histopathology features varied according to the site and severity of each lesion. In most of the 9 cases, opacities started from a subpleural area and peripheral structures were more severely damaged based on gross views and pathological examinations. Fibrosis could occur in early stages of infection and this was supported by radiological and pathological findings. The radiological features of COVID-19 pneumonia, at the critically ill stage, were diffuse ground-glass opacities with consolidation, interstitial thickening, and fibrous stripes, which was based in the fibrous tissue proliferation in the alveolar and interlobular septa, and filled alveoli with organizing exudation. Fungal and bacterial co-infections were also observed in 6 cases.Typical imaging features can be correlated with underlying pathological findings. Combining assessments of imaging features with pathological findings therefore can enhance our understanding of the histopathological mechanism of COVID-19 pneumonia, and facilitate early radiological diagnosis and prognosis estimation of COVID-19 pneumonia, which has important implications for the development of clinical targeted treatments and research related to COVID-19 pneumonia.Entities:
Mesh:
Year: 2021 PMID: 33761714 PMCID: PMC9282075 DOI: 10.1097/MD.0000000000025232
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Demographics and clinical characteristics of the COVID-19 patients.
| Serial number | Gender /Age | Days from onset to death | Days from onset to last CT | Days from onset to last Chest Radiograph | Medical past histories | Comorbidities | Mechanical ventilation |
| 1 (Case1 Fig. | F/66 | 14 | 5 | 9 | Hypertension | K, C | Non-invasive |
| 2 (Case2 Fig. | M/85 | 18 | 11 | - | Hypertension, cerebral infarction | K, C, M, A | Non-invasive |
| 3 | F/67 | 20 | 10 | 15 | None | L, C, M | invasive |
| 4 | F/86 | 23 | 7 | 19 | Hypertension, CHD, cerebral infarction | K, C, M, L, A | Non-invasive |
| 5 (Case3 Fig. | M/70 | 27 | 12 | 22 | Hypertension | cardiopulmonary arrest | Non-invasive |
| 6 | M/78 | 27 | 6 | 25 | Hypertension, CHD, T2DM | K, C, M | invasive |
| 7 | M/51 | 29 | 5 | 23 | Hypertension, Gout | A, C | Non-invasive |
| 8 (Case4 Fig. | M/62 | 31 | 24 | 20 | None | K, C | invasive |
| 9 (Case5 Fig. | F/53 | 34 | 18 | 28 | None | A, L, C, M | Non-invasive |
A = anemia (hemoglobin<100 g/L and red blood cell count<3.8 × 1012/L), C = coagulation disorders (prothrombin time>14 seconds, partially activated prothrombin time>38 seconds and D-dimer>0.5 μg/ml), CHD = coronary heart disease, K = chronic kidney disease, stage III-V (eGFR < 60 ml/minute/1.73m2), L = liver function damage (alanine aminotransferase>50U/L glutamic oxaloacetic transaminase>40U/L and cholinesterase<4500U/L), M = myocardial damage (myoglobin>100ng/ml, troponin>0.2pg/ml and lactate dehydrogenase>240U/L), T2DM = type 2 diabetes mellitus.
Summary of the final laboratory examinations of the COVID-19 patients.
| Index | Values; Median (IQR) | Normal range |
| White blood cell count × 109/L | 14.9 (13.1–17.1) | 3.5–9.5 |
| Neutrophil count × 109/L | 14.6 (12.2–17.0) | 1.8–6.3 |
| Lymphocyte count × 109/L | 0.73 (0.62–0.84) | 1.1–3.2 |
| Red blood cell count × 1012/L | 4.0 (3.8–4.2) | 3.8–5.5 |
| Hemoglobin, g/L | 119.0 (113.0–127.5) | 130–175 |
| Platelet count × 109/L | 167.0 (116.5–169.5) | 125–350 |
| Alanine aminotransferase ALT, U/L | 107.5 (78.2–158.7) | ≤41 |
| Creatinine, μmol/L | 194.4 (93.2–339.8) | 59–104 |
| Lactate dehydrogenase, U/L | 583.0 (502.5–589.0) | 135–225 |
| Hypersensitive cardiac troponin I, pg/ml | 206.6 (110.3–962.7) | ≤15.6 |
| B-type natriuretic peptide, pg/mL | 156.8 (120.3–567.8) | <285 |
| D-dimer, μg/ml | 16.6 (12.5–34.3) | <0.5 |
| Procalcitonin, ng/ml | 0.12 (0.12–0.12) | 0.02–0.05 |
| C-reactive protein, mg/L | 160.0 (152.7–160.0) | <10 |
| Ferritin, μg/L | 1600 (1550–1800) | 30–400 |
| Erythrocyte sedimentation rate, mm/h | 75.0 (59.5–82.0) | 0–15 |
| Interleukin 6, pg/ml | 10.8 (10.7–17.8) | <7 |
| eGFR, ml/min/1.73m2 | 26.7 (10.9–68.9) | 80–120 |
IQR = interquartile range.
Summary of histologic features in lungs of the COVID-19 patients.
| Histological features | Numbers of cases |
| Acute fibrinous exudate | 9 |
| Fibrosis | 9 |
| Hyaline membranes | 9 |
| Pulmonary edema | 9 |
| Hemorrhage | 9 |
| Pneumocyte hyperplasia | 9 |
| Thromboemboli | 7 |
| Secondary infections (bacterial or fungal infection) | 6 |
Figure 5A: “White lungs” (23rd day after onset). B: The increased transparence of bilateral lungs indicated an improvement (26th day after onset). C: A large degree of patchy ground-glass opacities with interstitial thickening or reticulation were observed in the left upper and lower lobes (28th day from onset). CR image showed bronchopneumonia in the left lower lobe. D: Alveolar structure destruction, widened alveolar septum and focal hemorrhagic necrosis. Diffuse alveolar damage with hyaline membrane formation and alveolar septal fibrosis, pulmonary congestion and edema in the left lower lobe (×40). E: Hyaline membrane and alveolar exudation in the left lower lobe (×100). F: Secondary bacterial infection in the left lower lobe: a large number of neutrophil exudations in the alveolar spaces (suppurative inflammation). The alveoli structures were still preserved (×100). Yellow circle: pathological sampling site for suppurative infection.